Role of Pseudomonas aeruginosa AmpR on β-lactam and non-β-lactam transient cross-resistance upon pre-exposure to subinhibitory concentrations of antibiotics.
暂无分享,去创建一个
[1] D. Curcio. Multidrug-resistant Gram-negative bacterial infections: are you ready for the challenge? , 2014, Current clinical pharmacology.
[2] S. Lory,et al. Deep sequencing analyses expands the Pseudomonas aeruginosa AmpR regulon to include small RNA-mediated regulation of iron acquisition, heat shock and oxidative stress response , 2013, Nucleic acids research.
[3] A. Pühler,et al. Complete sequence of broad-host-range plasmid pNOR-2000 harbouring the metallo-β-lactamase gene blaVIM-2 from Pseudomonas aeruginosa. , 2013, The Journal of antimicrobial chemotherapy.
[4] M. Falagas,et al. β-Lactam plus aminoglycoside or fluoroquinolone combination versus β-lactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis. , 2013, International journal of antimicrobial agents.
[5] Brendan F Gilmore,et al. Clinical relevance of the ESKAPE pathogens , 2013, Expert review of anti-infective therapy.
[6] R. Mehvar. Preface. State of Current Clinical Pharmacology. , 2013, Current clinical pharmacology.
[7] Hainen Yan,et al. Study on drug resistance of Pseudomonas aeruginosa plasmid-mediated AmpC β-lactamase. , 2013, Molecular medicine reports.
[8] K. Mathee,et al. A dynamic and intricate regulatory network determines Pseudomonas aeruginosa virulence , 2012, Nucleic acids research.
[9] Y. Kawamura,et al. MexXY multidrug efflux system of Pseudomonas aeruginosa , 2012, Front. Microbio..
[10] A. Oliver,et al. Genetic Markers of Widespread Extensively Drug-Resistant Pseudomonas aeruginosa High-Risk Clones , 2012, Antimicrobial Agents and Chemotherapy.
[11] A. Oliver,et al. Unusual diversity of acquired β-lactamases in multidrug-resistant Pseudomonas aeruginosa isolates in a Mexican hospital. , 2012, Microbial drug resistance.
[12] M. Toleman,et al. Genetic and Biochemical Characterization of an Acquired Subgroup B3 Metallo-β-Lactamase Gene, blaAIM-1, and Its Unique Genetic Context in Pseudomonas aeruginosa from Australia , 2012, Antimicrobial Agents and Chemotherapy.
[13] P. Nordmann,et al. Genetic support and diversity of acquired extended-spectrum β-lactamases in Gram-negative rods. , 2012, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.
[14] Pranita D. Tamma,et al. Combination Therapy for Treatment of Infections with Gram-Negative Bacteria , 2012, Clinical Microbiology Reviews.
[15] S. Lory,et al. The Regulatory Repertoire of Pseudomonas aeruginosa AmpC ß-Lactamase Regulator AmpR Includes Virulence Genes , 2012, PloS one.
[16] N. Boyd,et al. Combination Antibiotic Therapy for Empiric and Definitive Treatment of Gram‐Negative Infections: Insights from the Society of Infectious Diseases Pharmacists , 2011, Pharmacotherapy.
[17] D. Andersson,et al. Persistence of antibiotic resistance in bacterial populations. , 2011, FEMS microbiology reviews.
[18] R. Hancock,et al. The intrinsic resistome of Pseudomonas aeruginosa to β-lactams , 2011, Virulence.
[19] K. Mathee,et al. Co-regulation of β-lactam resistance, alginate production and quorum sensing in Pseudomonas aeruginosa , 2011, Journal of medical microbiology.
[20] R. Hancock,et al. Creeping baselines and adaptive resistance to antibiotics. , 2011, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[21] E. Ernst,et al. Is double coverage of gram-negative organisms necessary? , 2011, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[22] Robert E. W. Hancock,et al. The Sensor Kinase CbrA Is a Global Regulator That Modulates Metabolism, Virulence, and Antibiotic Resistance in Pseudomonas aeruginosa , 2010, Journal of bacteriology.
[23] M. Wolff,et al. Multirésistance chez Pseudomonas aeruginosa - Vers l’impasse thérapeutique ? , 2010 .
[24] L. Rice,et al. Progress and Challenges in Implementing the Research on ESKAPE Pathogens , 2010, Infection Control & Hospital Epidemiology.
[25] T. Bannerman,et al. Synergy Testing by Etest, Microdilution Checkerboard, and Time-Kill Methods for Pan-Drug-Resistant Acinetobacter baumannii , 2010, Antimicrobial Agents and Chemotherapy.
[26] Wei-hua Zhao,et al. β-Lactamases identified in clinical isolates of Pseudomonas aeruginosa , 2010, Critical reviews in microbiology.
[27] R. Flamm,et al. Comparison of Broth Microdilution, Agar Dilution, and Etest for Susceptibility Testing of Doripenem against Gram-Negative and Gram-Positive Pathogens , 2010, Journal of Clinical Microbiology.
[28] A. Gales,et al. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy , 2010, Expert review of anti-infective therapy.
[29] F. Barbier,et al. [Multi-drug resistant Pseudomonas aeruginosa: towards a therapeutic dead end?]. , 2010, Medecine sciences : M/S.
[30] K. Kerr,et al. Pseudomonas aeruginosa: a formidable and ever-present adversary. , 2009, The Journal of hospital infection.
[31] M. Page,et al. Prospects for the next anti-Pseudomonas drug. , 2009, Current opinion in pharmacology.
[32] Nancy D. Hanson,et al. Antibacterial-Resistant Pseudomonas aeruginosa: Clinical Impact and Complex Regulation of Chromosomally Encoded Resistance Mechanisms , 2009, Clinical Microbiology Reviews.
[33] R. Hancock,et al. Regulation of virulence and antibiotic resistance by two-component regulatory systems in Pseudomonas aeruginosa. , 2009, FEMS microbiology reviews.
[34] George A. Jacoby,et al. AmpC β-Lactamases , 2009, Clinical Microbiology Reviews.
[35] F. Baquero,et al. Antibiotics and antibiotic resistance in water environments. , 2008, Current opinion in biotechnology.
[36] H. Giamarellou,et al. Current therapies for pseudomonas aeruginosa. , 2008, Critical care clinics.
[37] Varsha Gupta. Metallo beta lactamases in Pseudomonas aeruginosa and Acinetobacter species , 2008, Expert opinion on investigational drugs.
[38] J. Davies,et al. The world of subinhibitory antibiotic concentrations. , 2006, Current opinion in microbiology.
[39] M. Jacobs,et al. Activity of Retapamulin against Streptococcus pyogenes and Staphylococcus aureus Evaluated by Agar Dilution, Microdilution, E-Test, and Disk Diffusion Methodologies , 2006, Antimicrobial Agents and Chemotherapy.
[40] Clinical,et al. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : Approved standard , 2006 .
[41] K. Soares-Weiser,et al. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. , 2006, The Cochrane database of systematic reviews.
[42] J. Mcgowan. Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum. , 2006, American journal of infection control.
[43] C. Koh,et al. Pseudomonas aeruginosa AmpR Is a Global Transcriptional Factor That Regulates Expression of AmpC and PoxB β-Lactamases, Proteases, Quorum Sensing, and Other Virulence Factors , 2005, Antimicrobial Agents and Chemotherapy.
[44] K. Mathee,et al. Characterization of poxB, a chromosomal-encoded Pseudomonas aeruginosa oxacillinase. , 2005, Gene.
[45] J. Mekalanos,et al. ExsE, a secreted regulator of type III secretion genes in Pseudomonas aeruginosa , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[46] D. Livermore. Clinical significance of beta-lactamase induction and stable derepression in gram-negative rods , 1987, European Journal of Clinical Microbiology.
[47] P. Nordmann,et al. Biochemical Characterization of the Naturally Occurring Oxacillinase OXA-50 of Pseudomonas aeruginosa , 2004, Antimicrobial Agents and Chemotherapy.
[48] Martin Schuster,et al. Pseudomonas aeruginosa Biofilms Exposed to Imipenem Exhibit Changes in Global Gene Expression and β-Lactamase and Alginate Production , 2004, Antimicrobial Agents and Chemotherapy.
[49] Leonard Leibovici,et al. β lactam monotherapy versus β lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials , 2004, BMJ : British Medical Journal.
[50] H. Nikaido. Molecular Basis of Bacterial Outer Membrane Permeability Revisited , 2003, Microbiology and Molecular Biology Reviews.
[51] F. Odds,et al. Synergy, antagonism, and what the chequerboard puts between them. , 2003, The Journal of antimicrobial chemotherapy.
[52] D. Livermore,et al. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[53] K. Soares-Weiser,et al. Beta lactam monotherapy versus beta lactam‐aminoglycoside combination therapy for treating sepsis , 2001 .
[54] P. Bradford. Extended-Spectrum β-Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance Threat , 2001, Clinical Microbiology Reviews.
[55] M. Arendrup,et al. Comparison of Etest and a tablet diffusion test with the NCCLS broth microdilution method for fluconazole and amphotericin B susceptibility testing of Candida isolates. , 2001, The Journal of antimicrobial chemotherapy.
[56] T. Nakae,et al. Variation of the mexT gene, a regulator of the MexEF-oprN efflux pump expression in wild-type strains of Pseudomonas aeruginosa. , 2000, FEMS microbiology letters.
[57] S. Lory,et al. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen , 2000, Nature.
[58] S. Lory,et al. Complete genome sequence of Pseudomonas aeruginosa PAO 1 , an opportunistic pathogen , 2000 .
[59] N. Masuda,et al. Naomasa Pseudomonas aeruginosa Pumps in MexCD-OprJ , and MexXY-OprM Efflux Substrate Specificities of MexAB-OprM , 2000 .
[60] N. Hanson,et al. Regulation of inducible AmpC beta-lactamase expression among Enterobacteriaceae. , 1999, Current pharmaceutical design.
[61] T. Köhler,et al. Characterization of MexT, the Regulator of the MexE-MexF-OprN Multidrug Efflux System of Pseudomonas aeruginosa , 1999, Journal of bacteriology.
[62] Y. Carmeli,et al. Emergence of Antibiotic-Resistant Pseudomonas aeruginosa: Comparison of Risks Associated with Different Antipseudomonal Agents , 1999, Antimicrobial Agents and Chemotherapy.
[63] F. Baquero,et al. Selective compartments for resistant microorganisms in antibiotic gradients. , 1997, BioEssays : news and reviews in molecular, cellular and developmental biology.
[64] N. Gotoh,et al. Characterization of MexE–MexF–OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa , 1997, Molecular microbiology.
[65] D. Heinrichs,et al. Expression of the multidrug resistance operon mexA-mexB-oprM in Pseudomonas aeruginosa: mexR encodes a regulator of operon expression , 1996, Antimicrobial agents and chemotherapy.
[66] K. Poole,et al. Overexpression of the mexC–mexD–oprJ efflux operon in nfxB‐type multidrug‐resistant strains of Pseudomonas aeruginosa , 1996, Molecular microbiology.
[67] N. Masuda,et al. Quantitative correlation between susceptibility and OprJ production in NfxB mutants of Pseudomonas aeruginosa , 1996, Antimicrobial agents and chemotherapy.
[68] H. Nikaido,et al. Role of mexA-mexB-oprM in antibiotic efflux in Pseudomonas aeruginosa , 1995, Antimicrobial agents and chemotherapy.
[69] S. Busby,et al. Investigation of the Pseudomonas aeruginosa ampR gene and its role at the chromosomal ampC beta-lactamase promoter. , 1993, FEMS microbiology letters.
[70] S. Busby,et al. Cloning, sequencing and analysis of the structural gene and regulatory region of the Pseudomonas aeruginosa chromosomal ampC beta-lactamase. , 1990, The Biochemical journal.
[71] S. Lindquist,et al. Binding of the Citrobacter freundii AmpR regulator to a single DNA site provides both autoregulation and activation of the inducible ampC beta-lactamase gene , 1989, Journal of bacteriology.
[72] D. Livermore,et al. β-Lactamase Lability and Inducer Power of Newer β-Lactam Antibiotics in Relation to Their Activity Against β-Lactamase-Inducibility Mutants of Pseudomonas aeruginosa , 1987 .
[73] S. Normark,et al. Contribution of chromosomal beta-lactamases to beta-lactam resistance in enterobacteria. , 1986, Reviews of infectious diseases.
[74] S. Lindquist,et al. Chromosomal beta-lactam resistance in enterobacteria. , 1986, Scandinavian journal of infectious diseases. Supplementum.
[75] A. Stebbing,et al. Hormesis--the stimulation of growth by low levels of inhibitors. , 1982, The Science of the total environment.
[76] D. Caron,et al. Outer membrane permeability in Pseudomonas aeruginosa: comparison of a wild-type with an antibiotic-supersusceptible mutant , 1982, Antimicrobial Agents and Chemotherapy.
[77] T. Hennessey. Inducible β-lactamase in Enterobacter. , 1967 .
[78] T. Hennessey. Inducible beta-lactamase in Enterobacter. , 1967, Journal of general microbiology.